Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?
Transl Lung Cancer Res
.
2019 Oct;8(5):715-722.
doi: 10.21037/tlcr.2019.05.12.
Authors
Andrew J Piper
1
,
Kartik Sehgal
1
,
Daniel B Costa
1
,
Deepa Rangachari
1
Affiliation
1
Department of Medicine, Division of Medical Oncology, Beth Israel Deaconess Medical Center (a member of Beth Israel Lahey Health), Harvard Medical School, Boston, MA, USA.
PMID:
31737509
PMCID:
PMC6835108
DOI:
10.21037/tlcr.2019.05.12
No abstract available
Publication types
Editorial
Comment
Grants and funding
R37 CA218707/CA/NCI NIH HHS/United States